



## OPEN ACCESS

EDITED AND REVIEWED BY  
Peter Boross,  
Genmab, Netherlands

\*CORRESPONDENCE  
Jeanette H. W. Leusen  
jleusen@umcutrecht.nl

<sup>†</sup>These authors have contributed  
equally to this work

SPECIALTY SECTION  
This article was submitted to  
B Cell Biology,  
a section of the journal  
Frontiers in Immunology

RECEIVED 12 August 2022  
ACCEPTED 22 August 2022  
PUBLISHED 13 September 2022

CITATION  
Chan C, Lustig M, Baumann N,  
Valerius T, van Tetering G and  
Leusen JHW (2022) Corrigendum:  
Targeting myeloid checkpoint  
molecules in combination with  
antibody therapy: A novel anti-cancer  
strategy with IgA antibodies?  
*Front. Immunol.* 13:1017924.  
doi: 10.3389/fimmu.2022.1017924

COPYRIGHT  
© 2022 Chan, Lustig, Baumann,  
Valerius, van Tetering and Leusen. This  
is an open-access article distributed  
under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#).  
The use, distribution or reproduction  
in other forums is permitted, provided  
the original author(s) and the  
copyright owner(s) are credited and  
that the original publication in this  
journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is  
permitted which does not comply with  
these terms.

# Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?

Chilam Chan<sup>1</sup>, Marta Lustig<sup>2</sup>, Niklas Baumann<sup>2</sup>,  
Thomas Valerius<sup>2</sup>, Geert van Tetering<sup>1†</sup>  
and Jeanette H. W. Leusen<sup>1\*†</sup>

<sup>1</sup>Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands,  
<sup>2</sup>Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian  
Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany

## KEYWORDS

IgA, myeloid checkpoints, neutrophils (PMNs), cancer immunotherapy, immune checkpoint, antibodies, CD47-SIRPalpha axis, macrophages

## A Corrigendum on

**Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?**

by Chan C, Lustig M, Baumann N, Valerius T, van Tetering G and Leusen JHW (2022) *Front. Immunol.* 13:932155. doi: 10.3389/fimmu.2022.932155

In the published article, there was an error in **Figure 5** as published. The mitochondrion was misplaced in this figure. The corrected **Figure 5** and its caption appear below

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

